FDA Approved Xolair in 2024 for 450,000-Person Alpha-Gal Meat Allergy
Updated
Updated · WMUR Manchester · Jun 21
FDA Approved Xolair in 2024 for 450,000-Person Alpha-Gal Meat Allergy
2 articles · Updated · WMUR Manchester · Jun 21
Summary
Xolair became the first FDA-approved drug for alpha-gal syndrome in 2024, helping reduce severe reactions after accidental exposure to meat rather than reversing the allergy.
Tick bites trigger the condition by introducing alpha-gal sugar into the bloodstream, prompting antibodies that can later cause hives, breathing trouble or digestive symptoms hours after eating mammal meat or dairy.
About 450,000 Americans are estimated to have developed the syndrome, with diagnoses rising as awareness grows and the lone star tick expands beyond the eastern and southern U.S. into the Great Lakes and as far north as Martha's Vineyard.
Standard care still centers on avoiding beef, pork and lamb and carrying epinephrine, while some patients must also avoid dairy, gelatin and certain medical products made from cow or pig tissue.
The allergy can fade after several years in roughly 15% to 20% of patients, but researchers say preventing new tick bites remains critical and are studying other biologic drugs as possible treatments.